Clinical Trial: Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07495852) titled 'Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant' on March 23.

Brief Summary: Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Study Start Date: Feb. 17

Study Type: INTERVENTIONAL

Condition: Glaucoma

Intervention: DRUG: Gen 2 Travoprost Intracameral Implant

Travoprost

DRUG: Timolol eye drops 0.5%

Timolol 0.5%

PROCEDURE: Sham Procedure

Sham implant administration

OTHER: placebo eye drops

Artificial Tears

Recruitment Status: RECRUITING

Sponsor: Glaukos Corporation

Disclaimer: Curated by HT Syndication....